Mark J. Ratain to Carcinoma, Renal Cell
This is a "connection" page, showing publications Mark J. Ratain has written about Carcinoma, Renal Cell.
Connection Strength
0.914
-
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jun 01; 24(16):2505-12.
Score: 0.198
-
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol. 2005 Jun 01; 23(16):3726-32.
Score: 0.186
-
Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol. 2002 Nov 15; 20(22):4478-84.
Score: 0.156
-
Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther. 2013 Apr; 93(4):345-51.
Score: 0.079
-
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9.
Score: 0.070
-
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
Score: 0.059
-
Phase II oncology trials: let's be positive. Clin Cancer Res. 2005 Aug 15; 11(16):5661-2.
Score: 0.047
-
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001 Sep 15; 92(6):1567-76.
Score: 0.036
-
Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res. 2000 Sep; 6(9):3400-5.
Score: 0.033
-
Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial. Cancer. 1998 Apr 01; 82(7):1352-8.
Score: 0.028
-
Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib. Clin Cancer Res. 2015 Jan 15; 21(2):365-72.
Score: 0.022